Evolution of Combination Therapy As The Standard of Care
Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.
EP: 1.Trends in RCC Incidence
EP: 2.RCC Histologies
EP: 3.Risk Models and Prognostic Factors
EP: 4.Metastatic RCC: Prognosis and Recent Advances in Care
EP: 5.Biomarker Testing in RCC: Current Approaches
EP: 6.Biomarker Testing: Methodologies, Sample Types, and Emerging Data
EP: 7.Prognostic Value of Biomarkers in RCC
EP: 8.The Role of Genetic Mutations in Prognosis and Decision-Making
EP: 9.Comparison of Older First-Line, Single-Agent Therapies
EP: 10.Newer First-Line Combination Therapy Options
EP: 11.Evolution of Combination Therapy As The Standard of Care
EP: 12.Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
EP: 13.Safety and Efficacy Data: The CheckMate 214 Trial
EP: 14.Safety and Efficacy Data: The JAVELIN Renal 101 Trial
EP: 15.Safety and Efficacy Data: The KEYNOTE-426 Trial
EP: 16.Safety and Efficacy Data: The CheckMate 9ER Trial
EP: 17.Safety and Efficacy Data: The CLEAR Trial
EP: 18.Common Adverse Events with Single-Agent or Combination Therapy
EP: 19.Balancing Treatment Efficacy with Toxicity in Metastatic RCC
EP: 20.Strategies for Prevention and Management of Adverse Events
EP: 21.Patient-Specific Factors Impacting Treatment Choices in RCC
EP: 22.Considerations for Patient-Focused, Shared Decision-Making in RCC
EP: 23.Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
EP: 24.The Importance of Team-Based Management and Patient Communication
EP: 25.OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
EP: 26.Reflections on Novel Targets and Emerging Regimens for RCC
EP: 27.Clinical Pearls on Recent Advances and the Future of Treatment in RCC
EP: 28.Recap: Safety and Efficacy of Available Treatment Options and Considerations for Management of RCC
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
